ClinicalTrials.gg
TerminatedNCT07529912Updated Apr 24, 2026

Detecting Beta-amyloid in the Retina

An interventional study of Hyperspectral camera in Dementia and Alzheimer Disease, sponsored by Center for Eye Research Australia. Terminated at 1 site in Australia. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Center for Eye Research Australia · Not applicable, Interventional, and Other

How we know

Why this study was terminated
This study has been transferred to the Human Research Ethics Committee of St Vincent's Hospital Melbourne.

From the registry’s dates

  • Registered 10 years 2 months after the study started (first participant enrolled Feb 2016, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Alzheimer Disease with a site in Australia — 23 open to participants now, 42 under way, 18 of them phase 3. Alzheimer Disease · Australia.

Enrollment
109th of 168
186 · median 313
Started
2016
with 9 others
No phase
9 of 177
1 open now
Registered
170th of 177
by date

Among the 177 studies in Alzheimer Disease with a site in Australia, this one is the 109th largest by enrollment of the 168 interventional ones that give a count, is one of 10 that started in 2016, is one of 9 with no phase, and was the 170th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

23 of the 177 studies in Alzheimer Disease with a site in Australia are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 30 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Alzheimer Disease with a site in Australia, or all of them as a file.
02

Study summary

Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides detailed information about retinal structure. Previous research has demonstrated a potential role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. This study aims to further evaluate the use of hyperspectral retinal imaging in the assessment of individuals with dementia or those at risk of Alzheimer's disease.

Read the detailed description

The study involves retinal imaging using specialised cameras to capture detailed photographs of the eye. Imaging includes the use of two hyperspectral retinal cameras, which are similar to standard retinal cameras but use multi-wavelength (multicoloured) light instead of a conventional white-light flash.

These hyperspectral imaging devices are investigational and are not approved for routine clinical use in Australia. Their use in this research has been approved by the Human Research Ethics Committee of the Royal Victorian Eye and Ear Hospital following scientific and ethical review. The Therapeutic Goods Administration of Australia has been notified of their use under the Clinical Trial Notification (CTN) scheme.

03

Conditions studied

  • Dementia
  • Alzheimer Disease

Browse trials for

Keywords

  • Hyperspectral imaging
04

In context

Alzheimer Disease Reclassified

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's enrollment of 186 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 30 years and older
  • Diagnosis of Alzheimer's disease or no evidence of Alzheimer's disease (including control participants or those with other neurodegenerative conditions such as Parkinson's disease, Lewy body dementia, or vascular dementia)
  • Prior confirmation of Alzheimer's disease diagnosis by genetic testing or positron emission tomography (PET) scan (where applicable)
  • Able to undergo cognitive assessment if required (for control participants without recent testing within the past 6 months)
  • No major ocular conditions that would preclude retinal imaging
  • Willing and able to attend the Royal Victorian Eye and Ear Hospital
  • Able to attend with a friend or family member

Exclusion criteria

Exclusion Criteria:

  • Presence of significant ocular disease that prevents adequate retinal imaging
  • Inability to undergo study procedures or comply with study requirements
  • Any condition that, in the opinion of the investigators, would make participation unsafe or compromise data quality
06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • Other
    Detecting Beta-amyloid in the Retina

    Device: Hyperspectral camera

Interventions

  • DeviceHyperspectral camera

    Hyperspectral imaging is performed with the Metabolic Hyperspectral Retinal Camera (Optina Diagnostic, Montreal, Canada) and a prototype camera developed by researchers at the Centre for Eye Research Australia (CERA). The Metabolic Hyperspectral Retinal Camera is similar to a typical fundus imager but it incorporates a tunable light source which is able to transmit safe light levels within a wavelength range covering the visible to near infrared with a narrow bandwidth (\< 3nm). This instrument is capable of imaging a 26° field-of-view of retina at 90 wavelengths in less than a second, thus minimizing discomfort and limiting the influence of eye movements. The hyperspectral camera developed by CERA researchers is a non-mydriatic fundus camera that uses light emitting diodes (LEDs) and an optical variable bandpass filter to tune the illumination wavelengths.

07

What researchers measure

Primary outcomes

  1. Diagnostic performance of hyperspectral retinal imaging for detection of Alzheimer's disease-related beta-amyloid

    Assessment of whether hyperspectral retinal imaging can distinguish participants with Alzheimer's disease from cognitively healthy controls based on retinal spectral reflectance signatures (particularly in the 480-520 nm wavelength range). Performance will be evaluated using quantitative image-derived biomarkers and classification accuracy (e.g., sensitivity, specificity, and area under the receiver operating characteristic curve) generated from computer-assisted image analysis.

    Time frame: Single study visit (baseline imaging session; approximately 60 minutes)

08

Study locations

1 site
  • The Centre for Eye Research Australia
    Melbourne, Victoria 3002, Australia
09

References and documents

Individual participant data

Plan to share: Undecided — The plan for sharing individual participant data (IPD) has not yet been finalised. This is a multi-modal imaging study involving large hyperspectral and ophthalmic imaging datasets, and decisions regarding data sharing will depend on completion of primary analyses, data governance requirements, and ethical approvals. The feasibility of appropriate de-identification and secure sharing mechanisms is under review.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Jan 2024, 95 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 14, 2026
StartActual
Feb 4, 2016
Primary completionActual
Jan 9, 2024
CompletionActual
Jan 9, 2024
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07529912
Lead sponsor
Center for Eye Research Australia
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Feb 4, 2016
Primary completion
Jan 9, 2024
Completion
Jan 9, 2024
Last update
Apr 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion